- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03015246
Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence (BOS)
Biobehavioral Studies of Opioid Seeking: Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence
Study Overview
Status
Conditions
Detailed Description
If participants meet all the criteria, their involvement in the study (Phases 1 and 2 described below) will last for 10-13 weeks. Participants will be asked to stay at the research site for a minimum of 2 nights on 4 separate weeks and will have 22 office visits During that time, participants can't leave the unit unescorted or have visitors.
Participants will receive a medication called Buprenorphine/Naloxone. Buprenorphine/Naloxone is approved by the Food and Drug Administration (FDA) to treat opioid addiction, and is a safe and effective alternative to methadone. Participants will receive this medication every day. When participants are not living on the inpatient unit they will come to the research clinic every day to receive the medication.
On Day 1, one single 1-mL (0.2 teaspoon) blood sample will be collected to assess the effect of the Buprenorphine/Naloxone medication dose on gene expression pattern.
On each day of admission (once on weeks 3, 5 and 7), a single 1-mL (0.2 teaspoon) blood sample will be collected to assess the effect of the buprenorphine/naloxone medication dose on the participant's gene expression pattern.
On the 8 days while participants are an inpatient they will participate in experimental sessions that involve drug administration. On some days participants will receive morphine and on some days participants will receive oral medications called yohimbine and hydrocortisone that will be used to study stress responses. Each afternoon study staff will collect one blood sample (10 mL or 2 teaspoons) from a vein in the participant's arm; these samples will be used to measure biological signals of stress.
At the end of the study participants will be detoxified from the Buprenorphine/Naloxone medication over a 3-week outpatient period.
Study participants will be scheduled for one separate in-person visit at 1 month after week 11. At this follow-up visit participants will be asked to provide a urine sample and to complete questionnaires that ask about drug craving and use, withdrawal symptoms, risky situations for drug use, coping with stress, and consequences experienced from using drugs or being abstinent.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Kansas
-
Overland Park, Kansas, United States, 66212
- Vince and Associates
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Opioid dependent, as determined by structured clinical interview for DSM-IV (SCID) and Addiction Severity Index (ASI)
- Positive urine test for opiates
- Willing to use an adequate form of contraception for the duration of the study.
- Reads and writes English
- Participants must be in generally good health to be eligible. All candidates will receive a routine medical exam (history and physical) with standard laboratory tests (including blood and urine samples, EKG, mandatory TB testing, and voluntary HIV testing).
Exclusion Criteria:
- No candidate who has a current DSM-IV Axis I disorder other than Drug Dependence or a history of serious psychiatric problems (e.g. psychosis, bipolar or major depression) will be allowed to participate.
- Candidates meeting criteria for opioid or nicotine dependence will not be excluded, but those with other Substance Dependence disorders will be excluded. Those with Abuse of Alcohol, Cannabis, Cocaine, will not be excluded, but participants must provide an alcohol free breath specimen.
- No candidate with medical (neurological, cardiovascular, pulmonary or systemic) disorders will be allowed to participate. This will be determined with history and physical exam, standard laboratory testing (blood and urine), EKG, and TB tests (to avoid transmitting this communicable disease on the residential unit or in the laboratory).
- Candidates with evidence of cognitive impairment (based on reading ability and comprehension, will be excluded.
- Female candidates who are pregnant (urine pregnancy test), lactating, or not using adequate birth control methods (self-report) will be excluded.
- Candidates with injection phobia, or seeking treatment for opioid dependence will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Extended-Release Morphine + placebo stressor
Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses.
The placebo stressor will be administered on one day.
|
Dose (tailored to each participant based on his/her pre-experimental opioid use amount) is administered in 3 divided daily doses.
Lactose
|
Experimental: Buprenorphine/Naloxone low dose + placebo stressor
Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36
mg/day.
The placebo stressor will be administered on one day.
|
Lactose
Buprenorphine/Naloxone dose of 1.4/0.36
mg/day
Other Names:
|
Experimental: Buprenorphine/Naloxone moderate dose + placebo stressor
Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08
mg/day.
The placebo stressor will be administered on one day.
|
Lactose
Buprenorphine/Naloxone dose of 4.2/1.08
mg/day
Other Names:
|
Experimental: Buprenorphine/Naloxone high dose + placebo stressor
Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16
mg/day.
The placebo stressor will be administered on one day.
|
Lactose
Buprenorphine/Naloxone dose of 12.8/3.16
mg/day
Other Names:
|
Experimental: Extended-Release Morphine + active stressor
Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses.
Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
|
Dose (tailored to each participant based on his/her pre-experimental opioid use amount) is administered in 3 divided daily doses.
Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet
|
Experimental: Buprenorphine/Naloxone low dose + active stressor
Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36
mg/day.
The placebo stressor will be administered on one day.
Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
|
Buprenorphine/Naloxone dose of 1.4/0.36
mg/day
Other Names:
Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet
|
Experimental: Buprenorphine/Naloxone moderate dose + active stressor
Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08
mg/day.
Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
|
Buprenorphine/Naloxone dose of 4.2/1.08
mg/day
Other Names:
Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet
|
Experimental: Buprenorphine/Naloxone high dose + active stressor
Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16
mg/day.
Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
|
Buprenorphine/Naloxone dose of 12.8/3.16
mg/day
Other Names:
Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opioid price-inelasticity (economic demand)
Time Frame: measured once (end of session) in each of the 8 experimental sessions over 7 weeks
|
demand intensity (L) and demand elasticity (a) on hypothetical drug purchasing task
|
measured once (end of session) in each of the 8 experimental sessions over 7 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opioid Symptom Questionnaire: Agonist symptoms
Time Frame: Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
Total opioid agonist symptom score (16 items, each scored on 0-4 scale, for a scale score range of 0-64, with higher scores indicating higher opioid agonist symptoms)
|
Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
Opioid Symptom Questionnaire: Withdrawal symptoms
Time Frame: Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
Total opioid withdrawal symptom score (16 items, each scored on 0-4 scale, for a scale score range of 0-64, with higher scores indicating higher withdrawal symptoms)
|
Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
Visual Analog Scale (VAS) ratings
Time Frame: Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
VAS ratings will measure "liking", "good drug effect," "bad drug effect," "stimulated," "sedated", "[preferred opioid] craving", and "cigarette craving".
Each VAS is scored from 0 (not at all) to 100 (extremely).
|
Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
Profile of Mood States (POMS)
Time Frame: Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
72-item POMS questionnaire, which has several subscale scores
|
Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
Blood pressure
Time Frame: Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
Systolic/diastolic blood pressure (mm Hg)
|
Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
Heart rate
Time Frame: Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
Heart rate (beats/min)
|
Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
Pupil diameter
Time Frame: Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
Pupil diameter (mm) measured with digital pupillometer
|
Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline 0930, 1030, 1145, 1230, 1300, 1330, 1400, 1430, 1500, and 1600.
|
Plasma noradrenaline level
Time Frame: Measured once per session at 2-hours post Yohimbine in each of the 8 experimental sessions
|
Plasma noradrenaline level (µg/ml)
|
Measured once per session at 2-hours post Yohimbine in each of the 8 experimental sessions
|
Plasma BDNF level (µg/ml)
Time Frame: Measured once per session at 2-hours post Yohimbine in each of the 8 experimental sessions
|
Plasma brain derived neurotrophic factor level (pg/ml)
|
Measured once per session at 2-hours post Yohimbine in each of the 8 experimental sessions
|
Plasma IL-1Ra level (µg/ml)
Time Frame: Measured once per session at 2-hours post Yohimbine in each of the 8 experimental sessions
|
Plasma interleukin 1Ra level (pg/ml)
|
Measured once per session at 2-hours post Yohimbine in each of the 8 experimental sessions
|
Saliva cortisol level
Time Frame: Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline, 1.5, 2, 3 and 4 hours post Yohimbine in each of the 8 experimental sessions.
|
Saliva cortisol level (µg/dL)
|
Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline, 1.5, 2, 3 and 4 hours post Yohimbine in each of the 8 experimental sessions.
|
Saliva alpha-amylase level
Time Frame: Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline, 1.5, 2, 3 and 4 hours post Yohimbine in each of the 8 experimental sessions.
|
Saliva alpha-amylase level (U/dL)
|
Within-session change is being assessed, in each of 8 sessions over 7 weeks. Within-session measurements at baseline, 1.5, 2, 3 and 4 hours post Yohimbine in each of the 8 experimental sessions.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Narcotic-Related Disorders
- Opioid-Related Disorders
- Heroin Dependence
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Narcotic Antagonists
- Buprenorphine
- Naloxone
- Buprenorphine, Naloxone Drug Combination
- Morphine
Other Study ID Numbers
- BOS-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heroin Dependence
-
National Health Research Institutes, TaiwanUnknown
-
Shanghai Mental Health CenterShanghai Center of Biomedicine DevelopmentCompleted
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA)Completed
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA)Completed
-
National Health Research Institutes, TaiwanUnknown
-
University of PittsburghIndiana University of PennsylvaniaCompletedSubstance Use Disorders | Benzodiazepine Dependence | Alcohol Use Disorder | Substance Abuse | Opioid-use Disorder | Cocaine Use Disorder | Alcohol Abuse | Opiate Dependence | Alcohol Withdrawal | Benzodiazepine Abuse | Cocaine Abuse | Heroin Abuse | Cocaine Withdrawal | Opiate Withdrawal Syndrome | Heroin Overdoses | Heroin...United States
-
Icahn School of Medicine at Mount SinaiNational Center for Complementary and Integrative Health (NCCIH); University...RecruitingOpiate Use DisorderUnited States
-
Hurd,Yasmin, Ph.D.Jazz PharmaceuticalsRecruitingSubstance-Related Disorders | Opioid-Related Disorders | Opioid Use Disorder | Heroin AbuseUnited States
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA)Completed
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)Completed
Clinical Trials on Extended release morphine
-
University Health Network, TorontoCanadian Society of Hospital PharmacistsWithdrawn
-
Washington University School of MedicineTerminatedSpastic Cerebral PalsyUnited States
-
Actavis Inc.CompletedHealthyUnited States
-
Actavis Inc.Completed
-
Brigham and Women's HospitalNational Institute on Drug Abuse (NIDA); Arthritis FoundationCompletedDepression | Anxiety | Degenerative Disc Disease | Chronic Low Back PainUnited States
-
University of Colorado, DenverCompletedScoliosis | Pain Management | Spinal FusionUnited States
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompleted
-
Luye Pharma Group Ltd.Shandong Luye Pharmaceutical Co., Ltd.Completed
-
AstraZenecaWithdrawnHealthy Male Subjects | Pharmacokinetics | Safety | Food EffectUnited Kingdom
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy (HIBM)United States